Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MT103: Additional Phase I data

In an ongoing Phase I trial in 18 evaluable patients who received 0.015-0.06 mg/m 2/day of MT103, there were

Read the full 196 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE